+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Peritoneal Cancer - Pipeline Review, H1 2020

  • ID: 5017494
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 1595 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AB Science SA
  • Basilea Pharmaceutica Ltd
  • Eli Lilly and Co
  • Innate Pharma SA
  • Neon Therapeutics Inc
  • PsiOxus Therapeutics Ltd
  • MORE
Peritoneal Cancer - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H1 2020, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 83, 55, 2, 20, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 8 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB Science SA
  • Basilea Pharmaceutica Ltd
  • Eli Lilly and Co
  • Innate Pharma SA
  • Neon Therapeutics Inc
  • PsiOxus Therapeutics Ltd
  • MORE
  • Introduction
  • Peritoneal Cancer - Overview
  • Peritoneal Cancer - Therapeutics Development
  • Peritoneal Cancer - Therapeutics Assessment
  • Peritoneal Cancer - Companies Involved in Therapeutics Development
  • Peritoneal Cancer - Drug Profiles
  • Peritoneal Cancer - Dormant Projects
  • Peritoneal Cancer - Discontinued Products
  • Peritoneal Cancer - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Peritoneal Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Peritoneal Cancer - Pipeline by AB Science SA, H1 2020
  • Peritoneal Cancer - Pipeline by AbbVie Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Peritoneal Cancer - Pipeline by AIM ImmunoTech Inc, H1 2020
  • Peritoneal Cancer - Pipeline by AiVita Biomedical Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Altor Bioscience LLC, H1 2020
  • Peritoneal Cancer - Pipeline by ALX Oncology Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Amgen Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Anew Oncology Inc, H1 2020
  • Peritoneal Cancer - Pipeline by Antapodia Therapeutics Inc, H1 2020
  • Peritoneal Cancer - Dormant Projects, H1 2020
  • Peritoneal Cancer - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Peritoneal Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AB Science SA
  • AbbVie Inc
  • Advenchen Laboratories LLC
  • AIM ImmunoTech Inc
  • AiVita Biomedical Inc
  • Aldeyra Therapeutics Inc
  • Altor Bioscience LLC
  • ALX Oncology Inc
  • Amgen Inc
  • Anew Oncology Inc
  • Antapodia Therapeutics Inc
  • Apexigen Inc
  • Apollomics Inc
  • Apotex Inc
  • Aravive Inc
  • Arrien Pharmaceuticals LLC
  • Ascend Biopharmaceuticals Ltd
  • Ascenta Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • BeiGene Ltd
  • Bio-Path Holdings Inc
  • BioIntegrator Ltd
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Celsion Corp
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Clover Biopharmaceuticals
  • Clovis Oncology Inc
  • Context Therapeutics LLC
  • Corcept Therapeutics Inc
  • Cotinga Pharmaceuticals Inc
  • Cristal Therapeutics BV
  • CytomX Therapeutics Inc
  • EirGenix Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ellipses Pharma Ltd
  • ENB Therapeutics LLC
  • Epizyme Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Forty Seven Inc
  • Fujifilm Holdings Corp
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genmab AS
  • GlaxoSmithKline Plc
  • Gradalis Inc
  • I-Mab Biopharma Co Ltd
  • ImmunoGen Inc
  • IMPACT Therapeutics Inc
  • IMV Inc
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Innate Pharma SA
  • InSight Biopharmaceuticals Ltd
  • Ionic Pharmaceuticals LLC
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kupffer Biotherapeutics Inc
  • Kyowa Kirin Co Ltd
  • Leap Therapeutics Inc
  • Lipac Oncology LLC
  • Lokon Pharma AB
  • MabVax Therapeutics Holdings Inc
  • Mateon Therapeutics Inc
  • MaxCyte Inc
  • Merck & Co Inc
  • Merck KGaA
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Moderna Inc
  • Morvus Technology Ltd
  • MUCPharm Pty Ltd
  • Mycenax Biotech Inc
  • Neon Therapeutics Inc
  • Northlake International LLC
  • Novartis AG
  • NuCana Plc
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Oncoinvent AS
  • Oncolix Inc
  • Oncologie Inc
  • Oncolytics Biotech Inc
  • OncoQuest Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Orano Med LLC
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAbcine Inc
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Precigen Inc
  • Prestige BioPharma Pte Ltd
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • R-Pharm US LLC
  • Regeneron Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Rigel Pharmaceuticals Inc
  • Samyang Holdings Corp
  • Sanofi
  • Sanofi Pasteur SA
  • SELLAS Life Sciences Group Inc
  • Shenzen SiBiono GeneTech Co Ltd
  • Soricimed Biopharma Inc
  • Sotio AS
  • Sun Pharma Advanced Research Company Ltd
  • Sutro Biopharma Inc
  • Syndax Pharmaceuticals Inc
  • Synermore Biologics Co Ltd
  • Tara Immuno-Oncology Therapeutics LLC (Inactive)
  • Targovax ASA
  • Transgene SA
  • Vascular Biogenics Ltd
  • Verastem Inc
  • Vyriad Inc
  • Xcovery Holding Co LLC
  • Xencor Inc
  • Y-mAbs Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll